Small-animal PET/CT for monitoring the development and response to chemotherapy of thymic lymphoma in Trp53-/- mice

Martin A. Walter, Isabel J. Hildebrandt, Katrin Hacke, Adam L. Kesner, Owen Kelly, Gregory W. Lawson, Michael E. Phelps, Johannes Czernin, Wolfgang A. Weber, Robert H. Schiestl

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Transgenic mouse models of human cancers represent one of the most promising approaches to elucidate clinically relevant mechanisms of action and provide insights into the treatment efficacy of new antitumor drugs. The use of Trp53 transgenic mice (Trp53 knockout [Trp53-/-] mice) for these kinds of studies is, so far, restricted by limitations in detecting developing tumors and the lack of noninvasive tools for monitoring tumor growth, progression, and treatment response. Methods: We hypothesized that quantitative small-animal PET with 18F-FDG was able to detect the onset and location of tumor development, follow tumor progression, and monitor response to chemotherapy. To test these hypotheses, C57BL/6J Trp53-/- mice underwent longitudinal small-animal PET during lymphoma development and gemcitabine treatment. Trp53 wild-type (Trp53+/+) mice were used as controls, and histology after full necropsy served as the gold standard. Results: In Trp53+/+ mice, the thymic standardized uptake value (SUV) did not exceed 1.0 g/mL, with decreasing 18F-FDG uptake over time. Conversely, all Trp53-/- mice that developed thymic lymphoma showed increasing thymic glucose metabolism, with a mean SUV doubling time of 9.0 wk (range, 6.0-17.5 wk). Using an SUV of 3.0 g/mL as a criterion provided a sensitivity of 78% and a specificity of 100% for the detection of thymic lymphoma. Treatment monitoring with 18F-FDG PET correctly identified all histologic responses and relapses to gemcitabine. Conclusion: 18F-FDG small-animal PET can be used to visualize onset and progression of thymic lymphomas in Trp53-/- mice and monitor response to chemotherapy. Thus, 18F-FDG small-animal PET provides an in vivo means to assess intervention studies in the Trp53 transgenic mouse model.

Original languageEnglish (US)
Pages (from-to)1285-1292
Number of pages8
JournalJournal of Nuclear Medicine
Volume51
Issue number8
DOIs
StatePublished - Aug 2010
Externally publishedYes

Fingerprint

Fluorodeoxyglucose F18
Knockout Mice
Lymphoma
gemcitabine
Drug Therapy
Transgenic Mice
Neoplasms
Antineoplastic Agents
Histology
Therapeutics
Glucose
Recurrence
Growth

Keywords

  • Knock-out mice
  • Metabolic imaging
  • Molecular imaging
  • p53
  • Treatment monitoring

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Walter, M. A., Hildebrandt, I. J., Hacke, K., Kesner, A. L., Kelly, O., Lawson, G. W., ... Schiestl, R. H. (2010). Small-animal PET/CT for monitoring the development and response to chemotherapy of thymic lymphoma in Trp53-/- mice. Journal of Nuclear Medicine, 51(8), 1285-1292. https://doi.org/10.2967/jnumed.109.073585

Small-animal PET/CT for monitoring the development and response to chemotherapy of thymic lymphoma in Trp53-/- mice. / Walter, Martin A.; Hildebrandt, Isabel J.; Hacke, Katrin; Kesner, Adam L.; Kelly, Owen; Lawson, Gregory W.; Phelps, Michael E.; Czernin, Johannes; Weber, Wolfgang A.; Schiestl, Robert H.

In: Journal of Nuclear Medicine, Vol. 51, No. 8, 08.2010, p. 1285-1292.

Research output: Contribution to journalArticle

Walter, MA, Hildebrandt, IJ, Hacke, K, Kesner, AL, Kelly, O, Lawson, GW, Phelps, ME, Czernin, J, Weber, WA & Schiestl, RH 2010, 'Small-animal PET/CT for monitoring the development and response to chemotherapy of thymic lymphoma in Trp53-/- mice', Journal of Nuclear Medicine, vol. 51, no. 8, pp. 1285-1292. https://doi.org/10.2967/jnumed.109.073585
Walter, Martin A. ; Hildebrandt, Isabel J. ; Hacke, Katrin ; Kesner, Adam L. ; Kelly, Owen ; Lawson, Gregory W. ; Phelps, Michael E. ; Czernin, Johannes ; Weber, Wolfgang A. ; Schiestl, Robert H. / Small-animal PET/CT for monitoring the development and response to chemotherapy of thymic lymphoma in Trp53-/- mice. In: Journal of Nuclear Medicine. 2010 ; Vol. 51, No. 8. pp. 1285-1292.
@article{a310e85fe07442cfa55204b25ba96d7f,
title = "Small-animal PET/CT for monitoring the development and response to chemotherapy of thymic lymphoma in Trp53-/- mice",
abstract = "Transgenic mouse models of human cancers represent one of the most promising approaches to elucidate clinically relevant mechanisms of action and provide insights into the treatment efficacy of new antitumor drugs. The use of Trp53 transgenic mice (Trp53 knockout [Trp53-/-] mice) for these kinds of studies is, so far, restricted by limitations in detecting developing tumors and the lack of noninvasive tools for monitoring tumor growth, progression, and treatment response. Methods: We hypothesized that quantitative small-animal PET with 18F-FDG was able to detect the onset and location of tumor development, follow tumor progression, and monitor response to chemotherapy. To test these hypotheses, C57BL/6J Trp53-/- mice underwent longitudinal small-animal PET during lymphoma development and gemcitabine treatment. Trp53 wild-type (Trp53+/+) mice were used as controls, and histology after full necropsy served as the gold standard. Results: In Trp53+/+ mice, the thymic standardized uptake value (SUV) did not exceed 1.0 g/mL, with decreasing 18F-FDG uptake over time. Conversely, all Trp53-/- mice that developed thymic lymphoma showed increasing thymic glucose metabolism, with a mean SUV doubling time of 9.0 wk (range, 6.0-17.5 wk). Using an SUV of 3.0 g/mL as a criterion provided a sensitivity of 78{\%} and a specificity of 100{\%} for the detection of thymic lymphoma. Treatment monitoring with 18F-FDG PET correctly identified all histologic responses and relapses to gemcitabine. Conclusion: 18F-FDG small-animal PET can be used to visualize onset and progression of thymic lymphomas in Trp53-/- mice and monitor response to chemotherapy. Thus, 18F-FDG small-animal PET provides an in vivo means to assess intervention studies in the Trp53 transgenic mouse model.",
keywords = "Knock-out mice, Metabolic imaging, Molecular imaging, p53, Treatment monitoring",
author = "Walter, {Martin A.} and Hildebrandt, {Isabel J.} and Katrin Hacke and Kesner, {Adam L.} and Owen Kelly and Lawson, {Gregory W.} and Phelps, {Michael E.} and Johannes Czernin and Weber, {Wolfgang A.} and Schiestl, {Robert H.}",
year = "2010",
month = "8",
doi = "10.2967/jnumed.109.073585",
language = "English (US)",
volume = "51",
pages = "1285--1292",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "8",

}

TY - JOUR

T1 - Small-animal PET/CT for monitoring the development and response to chemotherapy of thymic lymphoma in Trp53-/- mice

AU - Walter, Martin A.

AU - Hildebrandt, Isabel J.

AU - Hacke, Katrin

AU - Kesner, Adam L.

AU - Kelly, Owen

AU - Lawson, Gregory W.

AU - Phelps, Michael E.

AU - Czernin, Johannes

AU - Weber, Wolfgang A.

AU - Schiestl, Robert H.

PY - 2010/8

Y1 - 2010/8

N2 - Transgenic mouse models of human cancers represent one of the most promising approaches to elucidate clinically relevant mechanisms of action and provide insights into the treatment efficacy of new antitumor drugs. The use of Trp53 transgenic mice (Trp53 knockout [Trp53-/-] mice) for these kinds of studies is, so far, restricted by limitations in detecting developing tumors and the lack of noninvasive tools for monitoring tumor growth, progression, and treatment response. Methods: We hypothesized that quantitative small-animal PET with 18F-FDG was able to detect the onset and location of tumor development, follow tumor progression, and monitor response to chemotherapy. To test these hypotheses, C57BL/6J Trp53-/- mice underwent longitudinal small-animal PET during lymphoma development and gemcitabine treatment. Trp53 wild-type (Trp53+/+) mice were used as controls, and histology after full necropsy served as the gold standard. Results: In Trp53+/+ mice, the thymic standardized uptake value (SUV) did not exceed 1.0 g/mL, with decreasing 18F-FDG uptake over time. Conversely, all Trp53-/- mice that developed thymic lymphoma showed increasing thymic glucose metabolism, with a mean SUV doubling time of 9.0 wk (range, 6.0-17.5 wk). Using an SUV of 3.0 g/mL as a criterion provided a sensitivity of 78% and a specificity of 100% for the detection of thymic lymphoma. Treatment monitoring with 18F-FDG PET correctly identified all histologic responses and relapses to gemcitabine. Conclusion: 18F-FDG small-animal PET can be used to visualize onset and progression of thymic lymphomas in Trp53-/- mice and monitor response to chemotherapy. Thus, 18F-FDG small-animal PET provides an in vivo means to assess intervention studies in the Trp53 transgenic mouse model.

AB - Transgenic mouse models of human cancers represent one of the most promising approaches to elucidate clinically relevant mechanisms of action and provide insights into the treatment efficacy of new antitumor drugs. The use of Trp53 transgenic mice (Trp53 knockout [Trp53-/-] mice) for these kinds of studies is, so far, restricted by limitations in detecting developing tumors and the lack of noninvasive tools for monitoring tumor growth, progression, and treatment response. Methods: We hypothesized that quantitative small-animal PET with 18F-FDG was able to detect the onset and location of tumor development, follow tumor progression, and monitor response to chemotherapy. To test these hypotheses, C57BL/6J Trp53-/- mice underwent longitudinal small-animal PET during lymphoma development and gemcitabine treatment. Trp53 wild-type (Trp53+/+) mice were used as controls, and histology after full necropsy served as the gold standard. Results: In Trp53+/+ mice, the thymic standardized uptake value (SUV) did not exceed 1.0 g/mL, with decreasing 18F-FDG uptake over time. Conversely, all Trp53-/- mice that developed thymic lymphoma showed increasing thymic glucose metabolism, with a mean SUV doubling time of 9.0 wk (range, 6.0-17.5 wk). Using an SUV of 3.0 g/mL as a criterion provided a sensitivity of 78% and a specificity of 100% for the detection of thymic lymphoma. Treatment monitoring with 18F-FDG PET correctly identified all histologic responses and relapses to gemcitabine. Conclusion: 18F-FDG small-animal PET can be used to visualize onset and progression of thymic lymphomas in Trp53-/- mice and monitor response to chemotherapy. Thus, 18F-FDG small-animal PET provides an in vivo means to assess intervention studies in the Trp53 transgenic mouse model.

KW - Knock-out mice

KW - Metabolic imaging

KW - Molecular imaging

KW - p53

KW - Treatment monitoring

UR - http://www.scopus.com/inward/record.url?scp=77956210819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956210819&partnerID=8YFLogxK

U2 - 10.2967/jnumed.109.073585

DO - 10.2967/jnumed.109.073585

M3 - Article

C2 - 20660381

AN - SCOPUS:77956210819

VL - 51

SP - 1285

EP - 1292

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 8

ER -